

# Product Information

**XPOVIO**<sup>®</sup>  
(selinexor)<sup>20 mg</sup>  
tablet

## INDICATIONS

- XPOVIO<sup>®</sup> (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

These indications are approved under accelerated approval based on response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

## DISTRIBUTION

XPOVIO can be accessed through the following authorized specialty pharmacies and specialty distributors:

### Authorized Specialty Pharmacies

<b>Biologics</b>	1.800.850.4306	biologics.mckesson.com	Fax 1.800.823.4506
<b>Onco360 Oncology Pharmacy</b>	1.877.662.6633	onco360.com	Fax 1.877.662.6355
<b>US Bioservices</b>	1.877.757.0667	usbioservices.com	Fax 1.888.899.0067

### Authorized Specialty Distributors

<b>ASD Healthcare</b>	1.800.746.6273	asdhealthcare.com
<b>Cardinal Health Specialty Distribution</b>	1.866.677.4844	specialtyonline.cardinalhealth.com
<b>McKesson Plasma &amp; Biologics</b>	1.877.625.2566	connect.mckesson.com
<b>McKesson Specialty</b>	1.800.482.6700	mscs.mckesson.com
<b>Oncology Supply</b>	1.800.633.7555	oncologysupply.com

Contact an XPOVIO field representative at [XPOVIOpro.com](http://XPOVIOpro.com)




**A patient support program by Karyopharm dedicated to providing assistance and resources to patients and their caregivers for XPOVIO<sup>®</sup> (selinexor) treatment.**

KaryForward can assist with:



**Insurance Coverage**



**Financial Assistance**



**Support and Resources**

To learn more, call 1-877-KARY4WD (1-877-527-9493), Monday through Friday, 8am-8pm ET or visit [KaryForward.com](http://KaryForward.com).

**Please see full [Prescribing Information](#).**

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: [medicalinformation@karyopharm.com](mailto:medicalinformation@karyopharm.com).

© 2020 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/18-00037 (06/20)



# Product Information

(cont'd)



## HOW SUPPLIED

XPOVIO are blue, round, bi-convex, and film-coated 20 mg tablets with “K20” debossed on one side and nothing on the other side. Tablets are packaged in a child-resistant blister pack. Four blister packs are supplied per carton.

### For RRMM

NDC	Contents	Tablets per Blister Pack	Weekly Dose	Carton
<u>NDC 72237-101-04</u>	4 blister packs (32 tablets total per carton)	Eight 20-mg tablets	80 mg twice weekly	
<u>NDC 72237-101-05</u>	4 blister packs (20 tablets total per carton)	Five 20-mg tablets	100 mg once weekly	
<u>NDC 72237-101-02</u>	4 blister packs (16 tablets total per carton)	Four 20-mg tablets	80 mg once weekly	
<u>NDC 72237-101-01</u>	4 blister packs (12 tablets total per carton)	Three 20-mg tablets	60 mg once weekly	

### For RR DLBCL

NDC	Contents	Tablets per Blister Pack	Weekly Dose	Carton
<u>NDC 72237-101-03</u>	4 blister packs (24 tablets total per carton)	Six 20-mg tablets	60 mg twice weekly	
<u>NDC 72237-101-06</u>	4 blister packs (16 tablets total per carton)	Four 20-mg tablets	40 mg twice weekly	
<u>NDC 72237-101-01</u>	4 blister packs (12 tablets total per carton)	Three 20-mg tablets	60 mg once weekly	
<u>NDC 72237-101-07</u>	4 blister packs (8 tablets total per carton)	Two 20-mg tablets	40 mg once weekly	

## STORAGE

- Store at or below 30°C (86°F).

Please see full [Prescribing Information](#).

For medical information, to report an adverse event or product complaint, please call: 1-888-209-9326 or email: [medicalinformation@karyopharm.com](mailto:medicalinformation@karyopharm.com).

© 2020 Karyopharm Therapeutics Inc. All rights reserved. US-XPOV-12/18-00037 (06/20)

